<?xml version="1.0" encoding="UTF-8"?>
<p id="p0165">Historically, such has been the case when an emerging pathogen causes substantial concern and threatens public health, emergency funding from governments results, only to not be sustained as the epidemic wanes. The recent lessons of severe acute respiratory syndrome, Middle East respiratory syndrome, Lassa fever, and to a lesser extent Ebola and others, loom large in this regard. When financial costs and profit are uncertain, the private sector will be reluctant to invest the magnitude of dollars necessary to bring such a vaccine to the point of licensure. If so, sustainable models for funding must be developed before the next large outbreaks of Zika.</p>
